Navigation Links
Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
Date:11/26/2012

Bonn/Magdeburg/Halle, 26/11/2012. A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer (Max Planck Research Unit for Enzymology of Protein Folding, Halle/Saale, Germany) and Dr. Frank Striggow (German Center for Neurodegenerative Diseases (DZNE)) have combined two already approved pharmaceutical substances with each other using a chemical linker structure. The objectives of this combination are to ensure maximum brain cell protection on the one hand and the suppression of unwanted side effects on the other. The new class of substances has now been registered with the European Patent Office as the DZNE's first patent in the form of a joint patent application with the Max Planck Research Unit. "The patent approval process can take several years. During this phase we are planning to conclude the pre-clinical development. It is our aim to start with clinical research and development at the earliest possible time. Overall, we have identified substantial therapeutic potential as far as chronic and age-related neurodegenerative diseases are concerned," comments Dr. Frank Striggow.

Multiple sclerosis is an inflammatory disease that affects the central nervous system. It destroys the insulation of the nerve cell signaling system, the myelin sheaths of the neural axons. The consequence of this process is the malfunction of signaling and finally cell death resulting in permanent neurological problems. The cause of multiple sclerosis is that the body itself attacks the cellular components of the myelin sheaths, the oligodendrocytes. Hence, the team of scientists under the direction of Prof. Gunter Fischer and Dr. Frank Striggow embarked on a search for intervention options that could protect brain cells from these attacks. The goal was not only to prevent the damage and loss of brain cells, but also to develop a medication that has a positive impact on cell regeneration.

The used components of the Cyclosporine and FK506 (tacrolimus)-series have been utilized in a chemically slightly altered form as immunosuppressant medications for a long time. Both suppress the cellular immune defenses. This effect is necessary in conjunction with organ transplants, but otherwise problematic for the organism. The specific combination of the two substances amplifies the protective effect on the nerve cells thanks to different but synergistic efficacy mechanisms. The impact on the immune defense is reduced at the same time, which results in fewer side effects. Both of these achievements were corroborated by experiments. An application for a patent protecting this new class of active ingredients has now been filed. Ascenion GmbH and Max Planck Innovation both attend the project as utilization partners of the DZNE and of the Max Planck Society.


'/>"/>

Contact: Dirk Frger
dirk.foerger@dzne.de
49-228-433-02260
Helmholtz Association of German Research Centres
Source:Eurekalert  

Related biology news :

1. New study finds a protein combination is best to consume post-workout for building muscle
2. New line of approach for combination therapy against melanoma
3. Insecticide resistance caused by recombination of 2 genes
4. Hormone combination effective and safe for treating obesity in mice
5. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
6. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
7. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
8. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
9. Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
10. Strip-till improves soybean yield
11. ORNL process improves catalytic rate of enzymes by 3,000 percent
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology: